An Open-label, Fixed-sequence, Two-period Phase I Trial to Evaluate the Effect of Multiple Oral Doses of Carbamazepine, a Strong CYP3A4 Inducer, on the Pharmacokinetics of Verducatib at Steady State in Healthy Male Trial Participants
Sponsor study identifier
interventional
20
1 country
1
Study Start
September 10, 2026
Actual (reported)Primary Completion
December 14, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 20, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The main objective of this trial is to investigate the effect of carbamazepine, a strong CYP3A4 inducer on the pharmacokinetics of verducatib at steady state.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 20, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 20, 2026
Actual (reported)August 24, 2026
Actual (reported)September 10, 2026
Actual (reported)December 14, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 20, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)
Up to 40 days.
Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)
Up to 40 days.
Minimum concentration of the analyte in plasma at steady state within a uniform dosing interval τ (Cmin,ss)
Up to 40 days.
Fixed-sequence treatment for all trial participants.
Verducatib
Carbamazepine
CRS Clinical Research Services Berlin GmbH
Berlin, 13627, Germany
First Submitted
August 20, 2026
First Posted
August 24, 2026
Study Start
September 10, 2026
Actual (reported)Primary Completion
A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Blood
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
December 14, 2026
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 20, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
September 23, 2026
Record last verified: 2026-09
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases(in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing
Study fields come from the primary record; confirmed relationships can use other sources. Selecting a record here changes its provenance and downloads, without replacing the displayed study fields.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: